Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PDE1A | P54750 | 3/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7458328 | 0.77 | ALDH1A1 (0.50) | PARGALDH1A1PDE1APDE1BPDE1C | |
| SCHEMBL18330056 | 0.76 | MAPT (0.44) | ALDH1A1POLBMAPTPCSK9MEN1 | |
| SCHEMBL19434471 | 0.73 | PDE1B (0.58) | ALDH1A1PDE1APDE1BPDE1CMAPT | |
| SCHEMBL3012870 | 0.72 | PDE1A (0.48) | ALDH1A1PDE1APDE1BPDE1CMEN1 | |
| SCHEMBL27077873 | 0.71 | NPBWR1 (0.59) | ALDH1A1PDE1APDE1BPDE1CMAPT | |
| SCHEMBL2873217 | 0.71 | ALDH1A1 (0.45) | ALDH1A1POLBPIK3CDMAPTPCSK9 | |
| SCHEMBL18330288 | 0.71 | ALDH1A1 (0.54) | ALDH1A1POLBPIK3CDMAPTMEN1 | |
| SCHEMBL4430296 | 0.70 | PDE3B (0.39) | ALDH1A1POLBPIK3CDKMT2AKDM4E | |
| SCHEMBL17508432 | 0.70 | MAPT (0.47) | PARGALDH1A1PDE1APDE1BPDE1C | |
| SCHEMBL16037273 | 0.70 | MAPT (0.53) | PARGALDH1A1PDE1BPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089597-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2022-03-24 | — | — | US | disclosed |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-20200392161-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | SCHRÖDINGER, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2019165073-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-06-20 | — | — | US | disclosed |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-06-20 | — | — | US | disclosed |
| EP-3310779-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-20150197524-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197528-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-9000001-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8846693-B2 | Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130018063-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2013-01-17 | — | — | US | disclosed |
| US-8273750-B2 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100273753-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20080188492-A1 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | INTRA-CELLULAR THERAPIES, INC (US) | 2008-08-07 | — | — | US | disclosed |
| EP-1888534-A2 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006133261-A2 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089597-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | PARG 4764/4885ALDH1A1 3953/4885PDE1A 1339/4885 |
| US-20100273753-A1 | ORGANIC COMPOUNDS | OPRD1, PGR, HTR1D | PARG 3452/4885ALDH1A1 698/4885PDE1A 102/4885 |
| US-20150197524-A1 | ORGANIC COMPOUNDS | OPRD1, HTR1D, DRD1 | PARG 3544/4885ALDH1A1 659/4885PDE1A 77/4885 |
| US-20150197528-A1 | ORGANIC COMPOUNDS | PDE3A, PDE9A, PDE2A | PARG 2220/4885ALDH1A1 122/4885PDE1A 16/4885 |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN3, PTPN5 | PARG 4723/4885ALDH1A1 4341/4885PDE1A 810/4885 |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | PARG 4764/4885ALDH1A1 3953/4885PDE1A 1339/4885 |
| US-20130018063-A1 | ORGANIC COMPOUNDS | PDE9A, PDE3A, PDE7A | PARG 2476/4885ALDH1A1 95/4885PDE1A 15/4885 |
| US-20080188492-A1 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | PDE9A, PDE3A, PDE7A | PARG 1783/4885ALDH1A1 110/4885PDE1A 18/4885 |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | PARG 4764/4885ALDH1A1 3953/4885PDE1A 1339/4885 |
| US-20200392161-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPRJ, PTPRC | PARG 4783/4885ALDH1A1 3858/4885PDE1A 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.